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Background: Regulatory T cells (Tregs) exhibit functional abnormalities in the context of hepatocellular carcinoma
(HCC). The microRNAs (miRNAs) are identified as the key modulators in Tregs. This study was to explore whether
the expression profiles of miRNAs of Tregs were different in HCC-activated Tregs and whether Foxp3 had special
effects on them.
Methods: We isolated HCC-activated Tregs from mice bearing HCC and compared the expression profiles of
miRNAs between HCC-activated Tregs and control Tregs by microarray. RNA interference against Foxp3 was also
performed through transfection of synthetic siRNAs to Tregs for analyzing the effect of Foxp3 on the expression of
miRNAs. Tregs isolated from HCC patients (n = 12) and healthy controls (n = 7) were used for validation of the
differentially expressed miRNAs. Finally, bioinformatic analysis was applied to infer their possible roles.
Results: We found nine specifically altered miRNAs in HCC-activated Tregs from the murine model. After
transfection with siRNAs against Foxp3, control Tregs showed obvious reduction of Foxp3 and five miRNAs were
significantly changed; HCC-activated Tregs exhibited a slight reduction of Foxp3 with three miRNAs significantly
changed. Tregs from HCC patients and healthy controls finally confirmed the up-regulation of four miRNAs
(hsa-miR-182-5p, hsa-miR-214-3p, hsa-miR-129-5p and hsa-miR-30b-5p). Following bioinformatic analysis suggested
these altered miRNAs would target eight important signaling pathways that could affect the functions of Tregs.
Conclusions: Our studies provided the first evidence that Tregs in HCC had the specifically altered expression of
miRNAs, which was affected by Foxp3. These results are useful both in finding new biomarkers and in further
exploring the functions of Tregs in HCC patients.
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Hepatocellular carcinoma (HCC) is the fifth most com-
mon cancer with relatively poor overall survival world-
wide [1]. Accumulating evidence implies that CD4+
CD25+ Foxp3+ regulatory T cells (Tregs) are the critical
factor affecting the progression and prognosis of HCC
[2,3]. HCC patients have increased Tregs in peripheral
blood, ascites and tumor tissue [4,5] and this prevalence* Correspondence: cmliang@fudan.edu.cn
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unless otherwise stated.of Tregs correlates with tumor stage and patients sur-
vival [6-8]. Not only the number but also the functional
phenotypes of Tregs are found abnormal in HCC. Tregs
in peripheral blood of HCC patients preferentially up-
regulate CCR6, which facilitates their migration to
tumor sites [9]. HCC-activated Tregs also express high
levels of glucocorticoid-induced tumor necrosis factor
receptor (GITR) and the inducible T cell co-stimulator
(ICOS), both of which are key mediators for the suppres-
sive function of Tregs [10]. In addition, the enhanced
suppressive function of Tregs is confirmed by different
studies in HCC patients [10-12].
Tregs constitute the key components in tumor immune
suppression [13]. Recent studies demonstrate that Tregs
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maturation of miRNAs, causes diminished Tregs and
compromises their suppressive function [16]. Following
studies demonstrate that miR-21 enhances the expres-
sion of Foxp3 while miR-31 suppresses it in human
Tregs [17]. miR-155, modulated by Foxp3, guarantees
competitive fitness of Tregs to the IL-2 signal by target-
ing suppressor of cytokine signaling 1 (SOCS1) protein
[18,19]. Deficiency of miR-146a, another recently con-
firmed microRNA in Tregs, leads to increased Tregs
with an impaired function [20].
However, it is still unclear at present for the following
questions in liver cancer research. Firstly, it is still un-
known that whether the expression profiles of miRNAs
of Tregs are different between control Tregs and HCC-
activated Tregs. Secondly, it is worthy to demonstrate
whether Foxp3 has a special role and influences the
expression profiles of miRNAs of Tregs in HCC. Thirdly,
if there are any specifically altered miRNAs in Tregs in
HCC, do they affect the functions of Tregs in HCC? It is
also need to be further explored. In this study, we used
Tregs from both the murine HCC model and HCC pa-
tients to answer these questions. We found nine miR-
NAs differentially expressed in HCC-activated Tregs and
alterations of these miRNAs were specific to HCC-
activated Tregs in the murine model. Foxp3 affected the
expression of these miRNAs. Tregs isolated from human
blood confirmed that four miRNAs up-regulated in
HCC patients. To our knowledge, this study was the first
attempt to characterize miRNAs perturbations and the
consequences in Tregs activated by HCC. Our data pro-
vided a systemic view on alterations in HCC-activated
Tregs, which was not only useful in finding new bio-
markers but also in further exploring the functions of
Tregs in HCC patients.Methods
Human Tregs separation
Peripheral blood mononuclear cells (PBMCs) were iso-
lated by density gradient sedimentation using Lymphosep
(Biowest, France) lymphocyte separation media. CD4+
CD25+ CD127− Tregs were enriched by human regulatory
T cell isolation kit (Miltenyi, German). In brief, non-CD4+
and CD127high cells were first depleted with microbeads
and then the pre-enriched CD4+ CD127dim cells went
through positive selection for CD25+ T cells. The purity
of Tregs was monitored via fluorescence-activated cell
sorting (FACS). The participants included HCC patients
(n = 12) and matched healthy controls (n = 7). Ethical
approval for the use of human subjects was obtained
from the Research Ethics Committee of Zhongshan
Hospital (Shanghai, PR China), and informed consent
was obtained from each participant.Cell lines and animals
Hepa 1–6 (CRL-1830), the murine HCC cell line, was ob-
tained from American Type Culture Collection (ATCC,
USA) and maintained in DMEM (Biowest) supplemented
with 10% FBS (Biowest). C57BL/6 J mice (6 to 8 weeks
of age) were purchased from the Chinese Academy of
Science and housed at the Animal Maintenance Facility
of the Shanghai Medical College, Fudan University. All
animal experiments were performed in conformity with
the National Institutes of Health Guide for the Care and
Use of Laboratory Animals. The Institutional Care of
Experimental Animals Committee of Fudan University
approved all animal protocols (Permit Number: SYXK
2009–0082).
Hepa 1–6 tumor bearing mice were established as fol-
lowing: mice were injected subcutaneously at the left
flank with 3 × 106 Hepa 1–6 cells in 200 μL RPMI 1640
(Biowest) or 200 μL RPMI 1640 alone as control. Three
groups of tumor bearing mice and control mice were
established (12 mice in each group). Two weeks after in-
oculation, the mice with visible tumor were sacrificed
and spleens were collected for isolation of Tregs using
mouse regulatory T cell isolation kit (Miltenyi). In brief,
CD4+ T cells were enriched by negative selection and
then went through positive selection for CD25+ T cells.
The purity of Tregs was monitored via FACS.
FACS analysis
For FACS, previously collected Tregs were stained with
regulatory T cell Kit (eBioscience, USA). Briefly, cells
were first incubated with anti-CD4-FITC and anti-
CD25-PE Abs at 4°C for 30 minutes. After washing, cells
were treated with fixation/permeabilization buffer and
then incubated with anti-Foxp3-PE-Cy5 Abs at 4°C for
30 minutes. Stained cells were subsequently analyzed
using an EPICS ALTRA Flow Cytometer (Beckman
Coulter, USA).
Transfection of siRNAs
Validated siRNAs against mouse Foxp3 and AllStars
negative control siRNAs were obtained from Qiagen
company in a FlexiTube format (Qiagen, German).
Four species of siRNAs against Foxp3 (SI01005319,
SI01005326, SI01005333 and SI01005340) were mixed
in equal amount to generate the Foxp3 siRNAs pool.
siRNAs were transfected into HCC-activated Tregs
and control Tregs using HiPerFect transfection reagent
(Qiagen) according to the manufacturer’s protocol.
Tregs were maintained in RPMI 1640 supplemented
with 10% heat-inactivated FBS, 5 μg/mL plate-bounded
anti-CD3, 5 μg/mL soluble anti-CD28 antibodies (Bio-
legend, USA) and 40 ng/mL rm IL-2 (PeproTech, USA)
at 37°C in humidified atmosphere containing 5% CO2
in air. Mixture of 100 nM of siRNAs and 6 μL of
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Then Tregs were harvested for further analysis forty-
eight hours after transfection. Two-step qRT-PCR and
FACS validated the efficiency of Foxp3 RNA interfer-
ence (RNAi).
miRNAs microarray
miRNAs microarray was assisted by Kangcheng Bio-
science Service Company (Shanghai). In brief, total RNA
was extracted from Tregs of each group using TRIzol
(Invitrogen, USA) and miRNeasy mini kit (Qiagen). RNA
quality and quantity was measured by NanoDrop-1000
spectrophotometer (Nanodrop Technologies, USA). miR-
NAs were labeled by the miRCURY™ Hy3™/Hy5™ Power
labeling kit (Exiqon, Denmark) and hybridized on the
miRCURYTMLNA Array (v.16.0) (Exiqon). The GenePix
4000B microarray scanner (Molecular Devices, USA)
scanned the slides. After normalization, volcano plot was
used to identify the differentially expressed miRNAs (fold
change ≥ 1.5 and P-value ≤ 0.05 fold change: the ratio of
normalized intensities, HCC-activated Tregs vs. control
Tregs; P-value: t-test results between groups). Three inde-
pendent arrays were performed for HCC-activated Tregs
and control Tregs. One array was performed for HCC-
activated Tregs transfected with siRNAs against Foxp3 or
control siRNAs respectively; one array was performed
for control Tregs transfected with siRNAs against
Foxp3 or control siRNAs respectively.
Real-time PCR
Total RNA was extracted from Tregs using TRIzol
(Invitrogen) and miRNeasy mini kit (Qiagen). RNA
quality and quantity was measured by NanoDrop-1000
spectrophotometer. miRNAs were transcribed to cDNA
by cDNA Synthesis Kit (Epicentre, USA) with specific
reverse transcription primers (The primers were listed
in Additional file 1: Table S1 ). Then the cDNA was
used for real time-PCR by miScript SYBRGreen PCR
Kit (Qiagen) with specific primers (The primers were
listed in Additional file 2: Table S2). For quantification
of Foxp3, the cDNA was first synthesized by cDNA Syn-
thesis Kit with Oligo(dT)21 primer, and the real time-
PCR was performed by miScript SYBRGreen PCR Kit
with specific primers (Invitrogen, the primers were
listed in Additional file 2: Table S2. The expression
levels of miRNAs were presented as 2-Δ Δ Ct or 2-Δ Ct
relative to U6 levels and the levels of mRNA were pre-
sented as 2-Δ Δ Ct relative to GAPDH levels.
Bioinformatic analysis
We predicted target genes using the online algorithm
TargetScan (Release 6.2, http://www.targetscan.org) [21].
The network of miRNAs and target genes was con-
structed in the software Exploratory Gene AssociationNetworks (EGAN) [22]. In brief, the total target genes
lists were imported into EGAN and further filtered
based on Tregs MeSH term (T-Lymphocytes, regula-
tory). Target genes with direct relation with Tregs MeSH
term were presented in the network and further ana-
lyzed for functional enrichment. Pathway enrichment
was based on the pathways database Kyoto Encyclopedia
of Genes and Genomes (KEGG, http://www.genome.jp/
kegg/) through DAVID Bioinformatics Resources 6.7
(http://david.abcc.ncifcrf.gov/home.jsp) [23].
Statistical analysis
Microarray data of miRNAs was analyzed by volcano
plot and the filtering criteria were set at expression fold
change ≥ 1.5 and P-value ≤ 0.05. Unsupervised hierarchical
clustering was performed by MultiExperiment Viewer
software (v4.8.1, USA). qRT-PCR validation data was ana-
lyzed by Mann–Whitney test. Statistical significance was
set at P-value < 0.05 (*) or P- value < 0.01 (**).
Results
miRNAs were differentially and specifically expressed in
HCC-activated Tregs
Tregs were isolated from spleens of mice and the purity of
Tregs was examined by fluorescence-activated cell sorting
(FACS); only the cells with the purity above 95%
(data not shown) were further processed for micro-
array analysis. Differentially expressed miRNAs in
HCC-activated Tregs were selected by volcano plot
filtering (fold change ≥ 1.5 and P-value ≤ 0.05). Eleven
miRNAs were identified as shown in Figure 1A. There
were four up-regulated miRNAs (mmu-miR-709, mmu-
miR-467a-3p, mmu-miR-182-5p and mmu-miR-25-5p)
and seven down-regulated miRNAs (mmu-miR-615-3p,
mmu-miR-409-3p, mmu-miR-680, mmu-miR-129-5p, mmu-
miR-151-5p, mmu-miR-142-5p and mmu-miR-30b-5p),
as the values presented in Table 1. Then we performed
unsupervised hierarchical clustering of the eleven miR-
NAs. We found these miRNAs clearly discriminated the
HCC-activated Tregs from control Tregs, as shown in
Figure 1B.
By TargetScan, we found that mmu-miR-25-5p, mmu-
miR-615-3p, mmu-miR-151-5p and mmu-miR-680 had
few target genes directly relating with Tregs in MeSH
database, so we excluded the four miRNAs for further
exploration. As mmu-miR-155 and mmu-let-7i have been
well documented in T cells [19,24,25], we observed that
mmu-miR-487b-5p and mmu-miR-214-3p were classified
into the same group with mmu-miR-155 and mmu-let-7i
respectively after hierarchical clustering (data not shown).
Therefore, we also included these two miRNAs for further
validation. To verify the credibility of qRT-PCR validation,
we included the miR-344e-5p as a negative control as it
did not pass volcano plot filtering (fold change = 1.85,
Figure 1 miRNAs differentially expressed in HCC-activated Tregs. (A) Differentially expressed miRNAs identified in the microarray. Eleven
miRNAs (red plots) passed the volcano plot filtering. (B) Unsupervised hierarchical clustering of differentially expressed miRNAs. Scale bar: up-regulated
(red), down-regulated (green). Log2 transformed data were used. C: HCC-activated Tregs (three replicates: 1, 2, 3); C’: control Tregs (three replicates: 1’,
2’, 3’). (C) Validation of the differentially expressed miRNAs by qRT-PCR. Values were presented as mean ± SEM from three independent experiments
performed in triplicates and were analyzed using the two-tailed Mann–Whitney test. **P < 0.01 for indicated comparison.
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validated by qRT-PCR, we found that mmu-miR-487b-
5p, mmu-miR-709, mmu-miR-182-5p, mmu-miR-214-3p
and mmu-miR-467a-3p were up-regulated in HCC-
activated Tregs, mmu-miR-142-5p, mmu-miR-30b-5p,
mmu-miR-409-3p and mmu-miR-129-5p were down-regulated (P < 0.01), while miR-344e-5p did not change
significantly, as shown in Figure 1C.
Foxp3 was involved in regulating the miRNAs
As Foxp3 is the master regulator in Tregs, it prompts us
to check whether these miRNAs would be specifically
Table 1 Differentially expressed miRNAs in HCC-activated
Tregs
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intensity (MFI) of Foxp3 in Tregs after magnetic sorting.
FACS results showed that the sorted Tregs had compar-
able percentages of Foxp3 positive cells; however, the
MFI was higher in HCC-activated Tregs compared with
control Tregs (Figure 2A). We transfected Tregs with
siRNAs against Foxp3 or negative controls and forty-
eight hours we determined the efficiency of silencing.
The qRT-PCR data demonstrated that mRNA levels of
Foxp3 reduced significantly (34%) in control Tregs,
whereas the levels did not change significantly in HCC-
activated Tregs (Figure 2B, left). While the FACS results
showed the protein levels of Foxp3 reduced in both
groups, we observed a more potent decrease of Foxp3 in
control Tregs after siRNA silencing (Figure 2B, right).
Then we examined the expression levels of the nine
miRNAs in Tregs from our microarray data after trans-
fection. In control Tregs, mmu-miR-487b-5p, mmu-miR-
214-3p, mmu-miR-30b-5p and mmu-miR-129-5p showed
significant down-regulation while mmu-miR-409-3p
showed significant up-regulation (Figure 2C, left). Com-
pared with control Tregs, although mmu-miR-487b-5p
and mmu-miR-129-5p showed similar down-regulation
in HCC-activated Tregs, mmu-miR-409-3p was actually
significantly down-regulated; mmu-miR-214-3p and
mmu-miR-30b-5p did not exhibit significant changes
(Figure 2C, right).
Expression patterns of the miRNAs in human Tregs
We wondered whether these miRNAs were also differ-
entially expressed in HCC patients. Because miR-487b-
5p, miR-709 and miR-467a-3p did not express in human
tissue (miRBase 19), we checked the expression levels of
the rest six miRNAs in Tregs from peripheral blood sam-
ples. Compared with the healthy controls, the expression
levels of hsa-miR-182-5p, hsa-miR-214-3p, hsa-miR-129-
5p and hsa-miR-30b-5p were significantly up-regulated inTregs from HCC patients while the hsa-miR-409-3p
and hsa-miR-142-5p did not show significant changes
(Figure 3).
Possible roles of target genes inferred by bioinformatic
analysis
The functions of these four miRNAs (hsa-miR-182-5p,
hsa-miR-214-3p, hsa-miR-129-5p and hsa-miR-30b-5p)
in human Tregs are not clear. Therefore, we applied bio-
informatic methods to explore their roles. Target genes
of these four miRNAs were predicted by TargetScan 6.2
and all the genes were imported to software EGAN. The
total 109 target genes involved in Tregs functions were
enriched based on MeSH database and constructed into
the network (Figure 4A). These target genes were further
analyzed by functional enrichment based on KEGG path-
ways via DAVID and eight pathways were enriched with
statistical significance (Figure 4B). Among these pathways,
two pathways were involved in cytokine signaling (Cyto-
kine-cytokine receptor interaction and Jak-STAT signaling
pathway); two pathways were associated with chemotaxis
(Chemokine signaling pathway and Cell adhesion mole-
cules (CAMs)); two pathways were related with immune
response to graft (Allograft rejection and Graft-versus-host
disease). The other two pathways were Intestinal immune
network for IgA production and NOD-like receptor signal-
ing pathway.
Discussion
In this study, we found nine differentially expressed miR-
NAs in Tregs from the murine HCC model, which were
modulated by Foxp3, and validated four of them in Tregs
from HCC patients. Bioinformatic analysis suggested the
four miRNAs had important roles by targeting genes in
several pathways affecting Tregs functions.
It has been reported that alterations of miRNAs in
CD4+ T cells and Tregs are correlated with certain acti-
vation states and diseases [26-28]. Our array data found
a group of differentially expressed miRNAs in Tregs from
the murine HCC model. Interestingly, the expression pat-
terns of these miRNAs were specific to HCC-activated
Tregs. It is supposed that Tregs suppress the immune re-
sponse in a context dependent way [29-31]. For example,
depleting the signal transducer and activator of transcrip-
tion 3 (STAT3), which is essential for proper development
of Th17 cells, results in failure of Tregs to suppress Th17
cell-mediated disease [32]. Assisted by bioinformatic
analysis, we selected ten miRNAs for qRT-PCR valid-
ation. The validation data were consistent with array re-
sults, indicating the up-regulation of five miRNAs and
down-regulation of four miRNAs. Because miRNAs can
simultaneously regulate a large number of genes, they
might be the proper candidate for this context dependent
modulation. We proposed that the specific tumor antigen,
Figure 2 (See legend on next page.)
Chen et al. BMC Cancer 2014, 14:489 Page 6 of 10
http://www.biomedcentral.com/1471-2407/14/489
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Figure 2 Special modulation of the miRNAs by Foxp3. (A) Representative FACS plots of Foxp3 were shown in control Tregs and HCC-activated
Tregs (left). Mean fluorescence intensity (MFI) was included in each of the panels. Summary of the Foxp3 MFI was presented (right) in control Tregs
and HCC-activated Tregs. (B) Tregs were transfected with Foxp3-specific siRNAs or negative controls and forty-eight hours later cells were
harvested. Expression levels of Foxp3 were determined by qRT-PCR (left) and representative FACS plots were shown in control Tregs and
HCC-activated Tregs (right). Results in (A) and (B) were presented as mean ± SEM of three independent experiments performed in triplicates
and analyzed by the two-tailed Student’s t-test. **P < 0.01 for indicated comparison. (C) Expression patterns of the nine miRNAs after Foxp3
silencing in control Tregs (left) and HCC-activated Tregs (right). The expression levels of each miRNAs after Foxp3 silencing were shown as fold
change relative to the negative control siRNAs. Data were from one microarray. * fold change > 1.5 for indicated comparison. Control_Tregs:
Tregs from control mice; HCC_Tregs: Tregs from mice bearing Hepa 1–6; Neg_RNAi: Tregs transfected with negative control siRNAs; Foxp3_RNAi: Tregs
transfected with siRNAs against Foxp3.
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contribute to the unique alterations in HCC-activated
Tregs, which was possibly mediated by miRNAs.
Because Foxp3 is the crucial transcription factor in
Tregs, we wondered whether these altered miRNAs were
affected by Foxp3. As Foxp3 has been reported to be up-
regulated in activated Tregs in some reports [33,34], we
first compared the MFI of Foxp3 in control Tregs and
HCC-activated Tregs. Consisted with previous reports,
we found higher MFI in HCC-activated Tregs. After
transfection of siRNAs against Foxp3, we determined
the mRNA and protein levels of Foxp3. Control Tregs
showed significant down-regulation of Foxp3 after silen-
cing at both the mRNA and protein levels; however,
HCC-activated Tregs showed slight down-regulation of
Foxp3 protein, and no significant changes of Foxp3
mRNA. So the increased expression of Foxp3 in HCC-Figure 3 Expression levels of the miRNAs in Tregs from healthy contr
determined by qRT-PCR in Tregs sorted from peripheral blood of healthy con
to U6 levels. Horizontal lines represented the mean and error bars represented
from HCC patients. Results were analyzed by the two-tailed Mann–Whitney teactivated Tregs might involve in the reduced efficacy of
Foxp3 RNAi. One report recently demonstrates that
under certain inflammatory milieu Foxp3 undergoes
phosphorylation, which affects its stability and function
[35]. This report and our present data support the hy-
pothesis that both the modification state and the expres-
sion level of Foxp3 in HCC-activated Tregs can affect
the efficiency of Foxp3 silencing.
We also found five miRNAs showed significant fold
changes after Foxp3 RNAi in control Tregs, among which
three miRNAs showed significant fold change in HCC-
activated Tregs. Two miRNAs (mmu-miR-214-3p and
mmu-miR-30b-5p) were significantly changed only in con-
trol Tregs. Our findings were consistent with previous
studies, which have demonstrated that Foxp3 modulates
the expression of miR-155 that maintains the functions of
Tregs [18]. Considering the relatively low silencing efficacyols and HCC patients. Expression levels of six selected miRNAs were
trols (n = 7) and HCC patients (n = 12). Expression data were normalized
the SEM. Control_Tregs: Tregs from healthy controls; HCC_Tregs: Tregs
st. *P < 0.05, **P < 0.01 for indicated comparison.
Figure 4 Bioinformatic analysis of target genes of the four miRNAs. (A) The network of target genes of the four miRNAs involved in Tregs
functions. Each ellipse represented a target gene predicted by TargetScan. The four rhombuses were miRNAs and the triangle was the MeSH
term of Tregs. Purple lines indicated genes involved in Tregs according to MeSH database; magenta lines outlined the miRNAs-target genes
relations. (B) Pathway enrichment of target genes. The y-axis represented pathways enriched based on predicted target genes of the four
miRNAs. The histogram indicated gene number in each pathway (upper black x-axis); the curve line indicated the P value (lower blue x-axis).
**P < 0.01 with the Bonferroni correction.
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tion of these two miRNAs were not so sensitive to Foxp3
levels compared with that of the other three miRNAs.
We further validated the expression levels of these
miRNAs in Tregs from HCC patients and healthy con-
trols. Because miR-487b-5p, miR-709 and miR-467a-3p
did not express in human tissue (miRBase 19), we vali-
dated the expression levels of the rest six miRNAs. Four
miRNAs showed significant changes in HCC-activated
Tregs compared with healthy controls. Interestingly,
compared with data from the murine model, two of the
four miRNAs (hsa-miR-182-5p and hsa-miR-214-3p)
showed the similar up-regulation while the other two
miRNAs (hsa-miR-129-5p and hsa-miR-30b-5p) showed
reverse changes. We were not sure whether this dis-
crepancy was due to the differences of species or HCC
tumor models. Further experiments were need to clarify
this question.
The functions of four up-regulated miRNAs were not
reported in Tregs and we performed bioinformatic ana-
lysis to infer their possible roles. The target genes with
direct relations with Tregs MeSH term were found sig-
nificantly involved in eight pathways. Two of them were
cytokine signaling, including genes IL6ST, IL6R, STAT3
and IL17A which have been reported to facilitate the dif-
ferentiation of Th17 by inhibiting Tregs induction
[36-38]. Up-regulation of these miRNAs might break thebalance between Th17 and Tregs and finally accelerate
the production of Tregs, which contributes to the abnor-
mal homeostasis of Tregs in HCC [9,39,40]. Another
two pathways related with chemotaxis, which has been
reported to be critical for the migration and distribution
of Tregs in HCC. CC chemokine receptor 6 (CCR6) axis
has an important role in recruiting Tregs to tumor sites
in HCC [9]; TGF-beta and macrophage-derived chemo-
kine (CCL22) signaling pathways induce aggregation of
Tregs at the tumor sites in HCC too [41]. These two
pathways included genes in chemotaxis and cell adhe-
sion such as CCR6, CCR7, CXCR1, SELE and ICOS
[9,42-44]. These alterations might contribute to the abnor-
mal distribution of Tregs in HCC at the tumor sites. We
also found two pathways relating with immune response
to allograft (Allograft rejection and Graft-versus-host dis-
ease). Although it is well established that Tregs are critical
for maintaining the tolerance to allograft [45-47], it is not
clear whether the same genes or pathways work similarly
in Tregs during the progression of HCC. These new clues
needed further exploring. IgA production is essential for
the intestinal homeostasis, in which Tregs are indispens-
able via secretion of TGF-beta [48,49]. It was possible that
Tregs applied the same mechanism via TGF-beta in HCC.
NOD-like receptor is one of the conserved pattern-
recognition receptors (PRRs) which included Toll-like re-
ceptors (TLRs) [50]. Previous studies have demonstrated
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tions in Tregs [51-54] and we proposed that NOD-like
receptors were new key PRRs in the context of HCC.
Conclusions
In summary, we confirmed nine differentially expressed
miRNAs in Tregs from the HCC murine model. These
miRNAs exhibited a specific expression pattern in HCC-
activated Tregs and were affected by Foxp3. Four miRNAs
were finally found to be up-regulated in HCC patients for
the first time. Bioinformatic analysis indicated the four
miRNAs (hsa-miR-182-5p, hsa-miR-214-3p, hsa-miR-129-
5p and hsa-miR-30b-5p) targeted eight signaling pathways
involved in Tregs. These results provided interesting in-
formation on the intrinsic functional changes occurred
in HCC-activated Tregs, which were worthy of further
exploration.
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